Review of IDH mutations and potential therapies for intrahepatic cholangiocarcinoma

Abstract

Cholangiocarcinoma (CCA) is an aggressive malignancy that arises from the biliary tract. Currently, the first-line therapy for advanced CCA is gemcitabine and cisplatin. However, 5-year survival remains low. It has become abundantly clear that a “one size fits all” approach no longer applies to the treatment of individual cancers, given the large amount of tumor heterogeneity. As such, research in recent years has focused on developing effective targeted therapies through genetic profiling of CCA tumors. IDH1 and IDH2 mutations are commonly found in intrahepatic CCA (ICCA). IDH mutations prevent hepatic progenitor cell differentiation and result in the persistence of progenitor-like and stem cells. These are more prone to alterations that promote tumor initiation. As such, IDH has been identified as a promising target for ICCA treatment. We herein review the role of IDH mutations in ICCA development, recent data for IDH inhibitors in ICCA treatment, and challenges within the field of targeted therapy for ICCA.

Keywords

Intrahepatic cholangiocarcinoma / IDH / targeted therapy / ivosidenib / mechanisms of resistance

References

[1] Blechacz B.Cholangiocarcinoma: current knowledge and new developments.Gut Liver2017;11:13-26 PMCID:PMC5221857

[2] Gad MM,Faisaluddin M.Epidemiology of cholangiocarcinoma; United States incidence and mortality trends.Clin Res Hepatol Gastroenterol2020;44:885-93

[3] Patel N.Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 States.Cureus2019;11:e3962 PMCID:PMC6436669

[4] Alabraba E,Bird N.Increased multimodality treatment options has improved survival for hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged.Eur J Surg Oncol2019;45:1660-7

[5] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81.

[6] Rizvi S,Hallemeier CL,Gores GJ.Cholangiocarcinoma-evolving concepts and therapeutic strategies.Nat Rev Clin Oncol2018;15:95-111. PMCID:PMC5819599

[7] Rizzo A.Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review.Cancer Treat Res Commun2021;27:100354

[8] Squires MH,Dillhoff M,Pawlik TM.Challenges of surgical management of intrahepatic cholangiocarcinoma.Expert Rev Gastroenterol Hepatol2018;12:671-81

[9] Santoni M,Kucharz J.Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.Cancer Immunol Immun2023;72:1365-79

[10] Rizzo A.First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: "and yet it moves!".Cancer Treat Res Commun2021;27:100335

[11] Javle M,Jain A.Biliary cancer: utility of next-generation sequencing for clinical management.Cancer2016;122:3838-47.

[12] Weinberg BA,Lindberg MR.Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.J Gastrointest Oncol2019;10:652-62 PMCID:PMC6657312

[13] Rodrigues PM,Paiva NA.Pathogenesis of cholangiocarcinoma.Annu Rev Pathol2021;16:433-63

[14] Sia D,Villanueva A.Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.Gastroenterology2013;144:829-40 PMCID:PMC3624083

[15] Wu MJ,Merritt J,Bardeesy N.Biology of IDH mutant cholangiocarcinoma.Hepatology2022;75:1322-37

[16] Valls C,Puig I.Intrahepatic peripheral cholangiocarcinoma: CT evaluation.Abdom Imaging2000;25:490-6

[17] Seo N,Choi JY.Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis.AJR Am J Roentgenol2017;209:W64-75

[18] Fujii T,DiNardo CD,Janku F.Targeting isocitrate dehydrogenase (IDH) in cancer.Discov Med2016;21:373-80

[19] Clark O,Mellinghoff IK.Molecular pathways: isocitrate dehydrogenase mutations in cancer.Clin Cancer Res2016;22:1837-42 PMCID:PMC4834266

[20] Rizzo A,Brandi G.IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?.Cancer Treat Res Commun2021;27:100356.

[21] Zhang W,Wang Y.Systemic treatment of advanced or recurrent biliary tract cancer.Biosci Trends2020;14:328-41.

[22] Brandi G.IDH inhibitors and immunotherapy for biliary tract cancer: a marriage of convenience?.Int J Mol Sci2022;23:10869 PMCID:PMC9503989

[23] Kohanbash G,Shrivastav S.Isocitrate dehydrogenase mutations suppress STAT1 and CD8⁺ T cell accumulation in gliomas.J Clin Invest2017;127:1425-37. PMCID:PMC5373859

[24] Klemm F,Bowman RL.Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells.Cell2020;181:1643-60.e17 PMCID:PMC8558904

[25] Bunse L,Bunse T.Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.Nat Med2018;24:1192-203.

[26] Wu MJ,Dubrot J.Mutant IDH inhibits IFNγ-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma.Cancer Discov2022;12:812-35 PMCID:PMC8904298

[27] Wang P,Zhang C.Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.Oncogene2013;32:3091-100 PMCID:PMC3500578

[28] Rizzato M,Munari G.Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.Eur J Cancer2022;166:165-75

[29] Zhu AX,Kim Y.Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Ann Surg Oncol2014;21:3827-34 PMCID:PMC4324507

[30] Boerner T,Pak LM.Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.Hepatology2021;74:1429-44 PMCID:PMC8713028

[31] Goyal L,Sheth RA.Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma.Oncologist2015;20:1019-27 PMCID:PMC4571807

[32] Churi CR,Wang Y.Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.PLoS One2014;9:e115383 PMCID:PMC4275227

[33] Zhu AX,Javle MM.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with idh1 mutation: the phase 3 randomized clinical clarIDHy trial.JAMA Oncol2021;7:1669-77 PMCID:PMC8461552

[34] Cleary JM,Daina A.Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.NPJ Precis Oncol2022;6:61 PMCID:PMC9440204

[35] Lowery MA,Janku F.Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.Lancet Gastroenterol Hepatol2019;4:711-20 PMCID:PMC7934945

[36] NCCN guidelines version: hepatobiliary cancers. 2022. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1438 [Last accessed on 31 Jul 2023]

[37] Salama V,Skwarska A.Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML).Cancer Res2020;80:6417

[38] Pauff JM,Janku F.A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.J Clin Oncol2021;39:TPS350

[39] Wang Y,Turcan S.Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.Sci Adv2020;6:eaaz3221 PMCID:PMC7176409

[40] Schvartzman JM,Koche RP.2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation.Proc Natl Acad Sci U S A2019;116:12851-6 PMCID:PMC6600935

[41] Sharma H.Development of novel therapeutics targeting isocitrate dehydrogenase mutations in cancer.Curr Top Med Chem2018;18:505-24

[42] Stewart MD,Arend RC.Homologous recombination deficiency: concepts, definitions, and assays.Oncologist2022;27:167-74. PMCID:PMC8914493

[43] Niger M,Casadei-Gardini A.Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: a propensity score-based study.Int J Cancer2022;151:1310-20

[44] Saha SK,Kleinstiver BP.Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.Cancer Discov2016;6:727-39 PMCID:PMC5458737

[45] Fujiwara H,Kato H.Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.Cancer Sci2018;109:3602-10 PMCID:PMC6215870

[46] Zeng L.Bromodomain: an acetyl-lysine binding domain.FEBS Lett2002;513:124-8

[47] Choe S,DiNardo CD.Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.Blood Adv2020;4:1894-905 PMCID:PMC7218420

[48] Wang F,DiNardo CD.Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.Nat Commun2021;12:2607 PMCID:PMC8110775

[49] Harding JJ,Shih AH.Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition.Cancer Discov2018;8:1540-7. PMCID:PMC6699636